| Human immunodeficiency virus I infection
Descovy for PrEP vs Delstrigo
Side-by-side clinical, coverage, and cost comparison for human immunodeficiency virus i infection.Deep comparison between: Descovy vs Delstrigo with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsDelstrigo has a higher rate of injection site reactions vs Descovy based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Delstrigo but not Descovy, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Descovy
Delstrigo
At A Glance
Oral
Daily
NRTI combination
Oral
Once daily
NNRTI/NRTI combination
Indications
- Human immunodeficiency virus I infection
- Human immunodeficiency virus I infection
Dosing
Human immunodeficiency virus I infection Adults and pediatric patients >=35 kg: one 200 mg/25 mg tablet once daily with or without food; pediatric patients 25 to <35 kg: one 200 mg/25 mg tablet once daily; 14 to <25 kg: one 120 mg/15 mg tablet once daily (with other antiretrovirals including DRV+COBI but not other PI/ritonavir or PI/cobicistat combinations); not recommended with eGFR 15-30 mL/min or <15 mL/min without chronic hemodialysis.
HIV-1 PrEP One 200 mg/25 mg tablet once daily orally with or without food in adults and adolescents >=35 kg with eGFR >=30 mL/min, or adults with eGFR <15 mL/min on chronic hemodialysis (dose after hemodialysis); not recommended with eGFR 15-30 mL/min or <15 mL/min without hemodialysis.
Human immunodeficiency virus I infection One tablet orally once daily with or without food in adults and pediatric patients weighing at least 35 kg.
With rifabutin co-administration Take one tablet of DELSTRIGO once daily plus one tablet of doravirine 100 mg (PIFELTRO) approximately 12 hours after the DELSTRIGO dose for the duration of rifabutin co-administration.
Contraindications
- Unknown or positive HIV-1 status when used for HIV-1 PrEP
- Co-administration with strong CYP3A inducers, including carbamazepine, oxcarbazepine, phenobarbital, phenytoin, enzalutamide, rifampin, rifapentine, mitotane, or St. John's wort
- Previous hypersensitivity reaction to lamivudine
Adverse Reactions
Most common (>=10%) Nausea (in antiretroviral treatment-naive adults with HIV-1 receiving FTC+TAF with EVG+COBI)
Serious Severe acute exacerbations of hepatitis B, immune reconstitution syndrome, new onset or worsening renal impairment, lactic acidosis/severe hepatomegaly with steatosis
Postmarketing Angioedema, urticaria, rash, acute renal failure, acute tubular necrosis, proximal renal tubulopathy, Fanconi syndrome
Most common (>=5%) Dizziness, nausea, abnormal dreams
Serious Severe acute exacerbation of hepatitis B, new onset or worsening renal impairment, bone loss and mineralization defects, immune reconstitution syndrome
Postmarketing Stevens-Johnson syndrome/toxic epidermal necrolysis, hepatitis, lactic acidosis, hepatic steatosis, rhabdomyolysis, acute renal failure, Fanconi syndrome, anaphylaxis, anemia
Pharmacology
Dual HIV NRTI combination; emtricitabine (FTC) and tenofovir alafenamide (TAF) each inhibit HIV-1 reverse transcriptase via nucleotide analog chain termination after intracellular phosphorylation, with TAF serving as a prodrug converted intracellularly to tenofovir and then to the active metabolite tenofovir diphosphate.
DELSTRIGO combines doravirine, an NNRTI that non-competitively inhibits HIV-1 reverse transcriptase; lamivudine, a nucleoside analogue NRTI that terminates HIV-1 DNA chain elongation after phosphorylation to lamivudine triphosphate; and tenofovir disoproxil fumarate, a nucleotide analogue prodrug that, following conversion to tenofovir diphosphate, competitively inhibits HIV-1 reverse transcriptase and causes DNA chain termination.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Descovy
- Covered on 5 commercial plans
- PA (1/12) · Step Therapy (1/12) · Qty limit (11/12)
Delstrigo
- Covered on 5 commercial plans
- PA (4/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Descovy
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (6/8)
Delstrigo
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (6/8)
Humana
Descovy
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (3/3)
Delstrigo
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$0
Gilead Advancing Access Patient Assistance Program/Medication Assistance Program (PAP/MAP)Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
$0/fillfill
Delstrigo or Pifeltro Savings CouponCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
DescovyView full Descovy profile
DelstrigoView full Delstrigo profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.